Background and Aims: Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (GFAP) are emerging biomarkers of axonal damage and astrocytic activation, both likely paramount in MS associated neurodegeneration. This evidence concerns the gene GFAP and myeloid sarcoma.